As of today, the PAH targeted therapy against Group 3 PH is not available, the knowledge of the mechanism by which CCND1 mediated PASMCs and other vascular cells if possible might offer new opportunity for the treatment of Group 3 PH. This evidence concerns the gene CCND1 and pulmonary arterial hypertension.